TW201417822A - Topical compositions for the treatment of acne - Google Patents

Abstract

The invention is directed to topical formulations comprising plant extracts together with additional ingredients. The invention is further directed to use of the formulations in treating acne. In particular, the invention is directed to a topical formulation comprising Portulaca oleracea extract, Rheum palmatum extract, Chrysanthemum indicum extract and Scutellaria baicalensis root extract or its active ingredient Baicalin, together with nordihydroguaiaretic acid and oleanolic acid.

Description

Topical composition for treating acne Field of invention

The present invention relates to topical formulations comprising plant extracts together with additional ingredients. The invention is more related to the use of the formulation for the treatment of acne.

Background of the invention

Acne vulgaris (cyst-type acne or "acne") is a common skin disease characterized by redness of the skin, acne (blackheads and whiteheads), papules (needle-like), pustules (sputum), nodules (large papules). ) with scars. Acne mostly affects the most dense parts of the skin's hair follicle sebaceous glands; these areas include the face, upper chest and back. Severe acne is inflammatory, but acne also has a non-inflammatory form. The formation of such lesions is due to changes in the skin structure of the hair follicle sebaceous gland units, hair follicles and their associated sebaceous glands, and this change requires androgen stimulation. Acne most often occurs during puberty and usually continues into adulthood. Acne is considered to be one of the most common skin diseases in Western countries. The prevalence of acne in adults is about 25%, while 90% of adolescents suffer from acne during the 12 to 24 years of age. Symptoms are characterized by lumps in the face, neck, back, chest and shoulders. The severity of acne varies from person to person and genetic factors play an important role. Its pathogenic factors include sebum secretion, follicular keratosis, and microbial populations. And the process of immunity and inflammation.

According to a broad theory, the initial stage of development of acne lesions is abnormal keratinocyte shedding, which prevents normal sebum discharge. An increase in circulating male hormones in adolescents stimulates sebum production, causing swelling of surrounding hair follicles. The combination of these conditions produces an environment conducive to the proliferation of Propionibacterium acnes in the sebaceous glands. The breeding acne bacteria secrete various inflammatory molecules and chemokines, which initiate local inflammatory reactions and may induce excessive proliferation of keratinocytes. However, evidence suggests that inflammatory conditions occur before the formation of the lesion, and that the occlusion is affected to some extent by the inflammation of the acne bacillus.

Current types of acne lesions can be classified into inflammatory and non-inflammatory lesions.

Non-inflammatory lesions are also known as acne. Non-inflammatory lesions are solid small white papules, typically less than 1 mm in diameter, containing a white debris core (closed acne) consisting of sebum and keratinized debris, or a dark gray debris core that is exposed to air and then oxidized (open Caused by sexual acne.

Inflammatory lesions include papules, pustules, and nodules. Inflammatory lesions range from high-temperature solidified erythematous papules, core pustules containing purulent material, to larger induration lesions. The latter, if its diameter is less than 5 mm, is defined as a nodule.

In view of the shortcomings of conventional acne treatments, there is still a need for a topical composition containing herbs for use in therapy.

Summary of invention

Embodiments of the present invention relate to extracts comprising Portulaca oleracea extract, Rheum palmatum extract, Chrysanthemum indicum extract and Scutellaria baicalensis root extract, or activity thereof Ingredients Baicalin, combined with a topical formulation of nordihydroguaiaretic acid and oleanolic acid. Further embodiments relate to the treatment or prevention of acne using the above formulations. According to some embodiments, the formulation further comprises dipotassium glycyrrhizate, Chamomilla recutita (matricaria) flower extract and Hamamelis virginiana (witch hazel) )) One or more.

According to some embodiments, the formulation further comprises one or more of salicylic acid, allantoin, and a-bisabolol. According to some embodiments, the formulation further comprises kaolin, zinc oxide, hippophae rhamnoides oil, usnic acid, hydroxyphenyl propamidobenzoic acid, titanium dioxide One or more. According to some embodiments, the formulation further comprises one or more of imidazolidinyl urea, methylchloroisothiazolinone, and methylisothiazolinone.

Some embodiments of the present invention relate to a purslane extract, a Sapindus mukorossi fruit extract, an ammonium laureth sulfate, a cocamidopropyl betaine, A topical formulation of at least one of cocoamide MEA (cocamide MEA) and cocamide DEA (cocamide DEA). According to some embodiments, the above formulations are used to treat or prevent acne.

According to some embodiments, the formulation provides a synergistic effect that encompasses reduced sebum secretion, skin oil absorption, anti-inflammatory activity, antibacterial activity, wound healing characteristics, antioxidant activity, reduced skin irritation, skin absorption of the formula, or any combination thereof.

A further embodiment of the invention is a method of treating acne comprising topically applying to a subject in need thereof, in a topical formulation as detailed herein.

The invention is illustrated herein with reference to the drawings, but only for purposes of illustration. The detailed description of the present invention is intended to be illustrative of the preferred embodiments of the invention Principles and opinions. In this regard, the detailed description of the invention is not intended to It will be obvious.

1A, 1B, 1C and 1D are graphical representations of comparison results comparing the therapeutic efficacy of a cream of an exemplary embodiment of the present invention with a previously poorly curative formulation in an individual suffering from acne. In particular, Figures 1A and 1B illustrate the results of a face cream of an embodiment of the present invention, while Figures 1C and 1D illustrate the results of a previously poorly formulated formula.

2A, 2B, 2C and 2D are graphical illustrations of comparison results, In an individual suffering from acne, the concealer treatment formulation of an exemplary embodiment of the present invention was compared to the therapeutic efficacy of a previously poorly formulated formulation. Figures 2A and 2B illustrate the results of concealing treatments in accordance with embodiments of the present invention, while Figures 2C and 2D illustrate the results of concealing treatment formulations of previously poorer efficacy.

Figure 3 is a graphical representation of the reduction in acne inflammatory lesions in patients treated with salicylic acid alone and with a mixture of salicylic acid and herbal extracts.

Detailed description of the preferred embodiment

An embodiment of the present invention comprises a purslane extract, a rhubarb extract, a chrysanthemum extract and a xanthium root extract, or an active ingredient baicalin, combined with nordihydroguaiaretic acid and Qi Dun A topical formula for fruit acids. Some embodiments of the present invention relate to the use of a extract comprising purslane extract, rhubarb extract, oil daisy extract and xanthium root extract, or an active ingredient baicalin, in combination with nordihydroguaiaretic acid A topical formulation of oleanolic acid for the treatment and/or prevention of acne.

According to some embodiments, the topical formulation further comprises one or more of the following agents: zinc oxide, kaolin, titanium dioxide, sea buckthorn oil, hydroxyphenyl propylamino benzoic acid, usnic acid, dipotassium glycyrrhizinate, chamomile (mother Chrysanthemum) flower extract, salicylic acid, glycerin, witch hazel (witch hazel) water, allantoin, bisabolol, or any combination thereof.

According to some embodiments, the topical formulation further comprises one or more of zinc oxide, kaolin, titanium dioxide, sea buckthorn oil, hydroxyphenyl propylaminobenzoic acid and usnic acid, or any combination thereof.

According to some embodiments, the topical formulation further comprises licorice One or more of dipotassium, chamomile (Matricaria) flower extract, salicylic acid, glycerin, witch hazel (witch hazel) water, allantoin and bisabolol, or any combination thereof.

According to some embodiments, the topical formulation comprises a purslane extract, a palm leaf rhubarb extract, a nectarine extract and a scutellaria root extract, or an active ingredient baicalin, in combination with nordihydroguaiaretic acid Oleanolic acid, and one or more of salicylic acid, allantoin, bisabolol, dipotassium glycyrrhizinate, chamomile (Matricaria) flower extract and North American witch hazel (Witch Hazel). According to some embodiments, the topical formulation is free of parabens. According to some embodiments, the pH of the formulation is between about 3.5 and 4.5. According to some embodiments, the pH of the formulation is between about 3.0 and 5.0. According to some embodiments, the pH of the formulation is between about 3.0 and 5.5. In some embodiments, the formulation is in the form of a cream.

According to some embodiments, the topical formulation comprises a purslane extract, a palm leaf rhubarb extract, a nectarine extract and a scutellaria root extract, or an active ingredient baicalin, in combination with nordihydroguaiaretic acid Oleanolic acid. According to some embodiments, the formulation further comprises one or more of kaolin, zinc oxide, titanium dioxide, sea buckthorn oil, and hydroxyphenyl acrylamidobenzoic acid. According to further embodiments, the formulation further comprises one or more of imidazolidinyl urea, methylchloroisothiazolinone and methylisothiazolinone. According to some embodiments, the topical formulation is free of parabens. According to some embodiments, the pH of the formulation is between about 7.0 and 8.0. In some embodiments, the formulation is in the form of a concealer treatment formulation.

Some embodiments of the invention relate to the extraction of purslane A topical formulation of at least one of a substance, a fruit extract, and a lauryl ammonium sulfate, cocoamidopropyl betaine, cocoamine MEA, cocoamine DEA. Other embodiments of the invention relate to the use of a purslane extract, sapindus extract and ammonium laureth sulfate, cocoamidopropyl betaine, cocoamine MEA, cocoamine DEA At least one of the partial formulas for treating acne. According to some embodiments, the formulation does not contain sodium dodecyl sulfate (SLS). According to some embodiments, the formulation is in the form of a clean gel.

According to some embodiments, the topical formulation comprises one or more of an anti-inflammatory component, an antimicrobial component, a conditioning sebum secreting component, a skin moisturizing component, an analgesic, an anti-irritant, an antioxidant, and any combination thereof.

According to some embodiments, the active ingredient of the topical formulation provides a synergistic effect for the treatment and/or prevention of acne. According to further embodiments, a combination of at least one of the active ingredients in the formulation with at least one of the other ingredients provides a synergistic effect for the treatment and/or prevention of acne. Synergistic utility can be direct, to treat/prevent a condition, indirect, such as by enhancing penetration of the formulation/active ingredient into the skin or reducing skin irritation, or both direct and indirect.

The use of zinc oxide helps to reduce the amount of sebum. Kaolin can be used to absorb excess oil and exudate from oily skin. Baicalin and palm leaf rhubarb can reduce androgen receptor expression and, therefore, can be used to reduce the sebaceous gland activity stimulating by androgen mediators, resulting in decreased sebum content. Therefore, the combination of palm leaf rhubarb and scutellaria, or its active ingredient baicalin, together with zinc oxide and/or kaolin, or any other equivalent ingredient, can synergistically reduce sebum of the skin. Secretion and oil absorption.

Hydroxyphenyl acrylamide benzoic acid, a synthetic avenanthramide, enhances the anti-inflammatory activity of herbal mixtures. In addition, the palm leaf rhubarb extract also has anti-inflammatory activity specific for acne because it inhibits interleukins such as IL-1α. Thus, according to some embodiments, hydroxyphenyl prolyl benzoic acid, or any equivalent component, and palm rhubarb can synergistically enhance the anti-inflammatory activity of the formulation.

Nordihydroguaiaretic acid and oleanolic acid reduce hyperkeratosis, inhibit inflammation and reduce sebum secretion by inhibiting 5α-reductase action and controlling bacterial growth. In addition, Usnic acid is known to have antibacterial activity, while Witch Hazel (Witch Hazel) water is known to have anti-inflammatory properties. Such ingredients, or equivalents, may be combined in a synergistic manner with herbal extracts having anti-inflammatory activity, such as purslane extract, palmetto rhubarb extract, oil daisy extract, and astragalus root extract or baicalin, Treating acne. Acne can also be treated synergistically when combined with an extract that regulates sebum secretion, such as palm leaf rhubarb extract and Astragalus root extract or baicalin. According to some embodiments, the above ingredients or their equivalents synergistically enhance the antibacterial activity against Acne bacillus when used in combination with a purslane extract. It is worth noting that the reduction in acne bacilli is associated with a reduction in inflammatory mediators and clinical improvement in acne. When combined with a purslane extract and a palm leaf rhubarb extract, the above ingredients can further synergistically enhance wound healing ability.

Sea buckthorn oil (sea buckthorn seed oil) can be used as a wound for healing. Therefore, the combination, or any other equivalent component, combined with herbal extracts with wound healing capabilities, such as purslane extract and palmatum rhubarb extract, Provide synergistic effects to soothe acne and reduce scarring. Sea buckthorn oil and North American Witch Hazel (Witch Hazel) water are more known antioxidants. Thus, the combination, or any other equivalent ingredient, synergistically enhances the antioxidant activity of the herbal extract, which reduces the severity and symptoms of acne.

Chamomile (Matricaria) flower extract has anti-inflammatory activity and can reduce skin irritation. Thus, the combination, or any other equivalent component, in combination with the herbal extract mixture, synergistically reduces inflammation and skin irritation in acne sufferers. Further, according to some embodiments, the formulation further comprises salicylic acid, which may cause skin irritation. The addition of a chamomile (Matricaria) flower extract can simultaneously reduce such skin irritation. Allantoin and bisabolol can also be added to reduce skin irritation, including irritation caused by the addition of salicylic acid.

According to a further embodiment, the topical formulation further comprises salicylic acid. According to a further embodiment, the topical formulation further comprises at least 0.3% w/w salicylic acid. According to a further embodiment, the topical formulation further comprises at least 0.4% w/w salicylic acid. According to a further embodiment, the topical formulation further comprises at least 0.5% w/w salicylic acid. According to further embodiments, the topical formulation further comprises about 1.0% w/w salicylic acid. According to a further embodiment, the topical formulation further comprises salicylic acid in the range of from 0.4 to 2.5% w/w. According to a further embodiment, the topical formulation further comprises salicylic acid in the range of from 0.5 to 2.0% w/w. According to a further embodiment, the topical formulation further comprises salicylic acid in the range of from 0.5 to 1.5% w/w. According to a further embodiment, the topical formulation further comprises salicylic acid in the range of from 0.5 to 1.0% w/w. According to further embodiments, the topical formulation further comprises salicylic acid in the range of 1.25-2% w/w.

According to a further embodiment, the topical formulation further comprises benzoyl peroxide. According to a further embodiment, the topical formulation further comprises at least 1.5% w/w benzoyl peroxide. According to a further embodiment, the topical formulation further comprises at least 2.0% w/w benzoyl peroxide. According to a further embodiment, the topical formulation further comprises at least 2.5% w/w benzoyl peroxide. According to a further embodiment, the topical formulation further comprises benzoic acid in the range of from 1.5 to 12.0% w/w. According to a further embodiment, the topical formulation further comprises benzoic acid in the range of from 2.0 to 11.0% w/w. According to a further embodiment, the topical formulation further comprises benzoic acid in the range of from 2.5 to 10.0% w/w.

According to some embodiments, the topical formulation has a pH between about 3.0 and 5.0. According to a further embodiment, the topical formulation has a pH between about 3.5 and 4.5. According to a further embodiment, the topical formulation has a pH between about 2.5 and 6.0. According to some embodiments, the topical formulation has a pH between about 6.0 and 9.0. According to a further embodiment, the topical formulation has a pH between about 7.0 and 8.0. According to a further embodiment, the topical formulation has a pH between about 6.5 and 8.5.

According to some embodiments, the herbal extract of the formulation has a combined concentration of at least 0.75%. According to some embodiments, the herbal extract of the formula has a combined concentration of at least 0.9%. According to some embodiments, the herbal extract of the formulation has a combined concentration of at least 1.0%. According to some embodiments, the herbal extract of the formulation has a combined concentration of between about 0.8 and 1.2%. According to some embodiments, the herbal extract of the formulation has a combined concentration of at least 8.0%. According to some embodiments, the herbal extract of the formula has a combined concentration of at least 9.0%. According to some embodiments, the herbal extract of the formulation has a combined concentration of at least 10.0%. According to some embodiments, the herbal extract of the formula has a combined concentration of between about 9.0 and 11%.

According to some embodiments, the amount of each of the herbal extracts of the formula is about 0.3%. According to some embodiments, the amount of each of the herbal extracts of the formula ranges from about 0.25 to 0.35%. According to some embodiments, the amount of each of the herbal extracts of the formula ranges from about 0.2 to 0.4%.

According to some embodiments, the formulation comprises at least 0.075% baicalin. According to some embodiments, the formulation comprises at least 0.085% baicalin. According to some embodiments, the formulation comprises at least 0.095% baicalin. According to a further embodiment, according to a further embodiment, the cream formulation comprises at least 0.1% baicalin. According to some embodiments, the concealer treatment formulation comprises at least 1.0% baicalin. According to some embodiments, the cream extract has a herbal extract concentration of from about 1.0% to about 1.6%. According to some embodiments, the concealer has a herbal extract concentration of about 9.0 to 11.0%. The formulations of the present invention can be formulated into a variety of preparations depending on the intended use, using conventional methods. These preparations include, but are not limited to, topical skin compositions for medical use, and topical skin cosmetic compositions.

Gels, ointments, soaps, creams and lotions can be used in the form of topical skin compositions for medical use and topical skin cosmetic compositions. The formulation can be applied in any suitable manner, i.e., via hand, spatula, spray or pad.

The formulation of the invention may be in the form of a face cream, concealer treatment, or a clean gel. The formulation of the present invention can be applied to all skin areas infected with acne, Or partial for each sore. The formulations of the present invention have high skin compatibility and low irritation when applied to human skin. According to some embodiments, the formulation is applied to the human body and subsequently removed, such as by a water wash.

When the topical composition of the present invention is used as a cosmetic composition, a cosmetic or dermatologically acceptable ingredient may optionally be incorporated in any desired combination and determined according to techniques well known in the art. According to some embodiments, the composition may include oils, fats, waxes, detergents, blending agents, pH adjusters, preservatives, solvents, viscosity modifiers, colorants, perfumes, dyes, and the like.

The composition may be oil-in-water, water-in-oil, water-in-oil-in-water, and water-in-oil emulsion, cream, ointment, aqueous solution, lotion, soap, paste, foam, emulsion, gel , ointments, oils, lotions, conditioners or aerosols.

According to an embodiment of the invention, the composition of the invention is administered once a day. According to other embodiments, the composition is administered twice daily, three times daily or more.

According to an embodiment of the invention, the composition is administered chronically.

According to some embodiments of the invention, the composition is administered for about 10 days or more, 20 days, 30 days, 60 days, 90 days, 120 days or more.

In some embodiments of the invention, the composition further comprises a detergent or surfactant, which is typically an anionic, cationic, nonionic or amphoteric surfactant. Typical anionic surfactants are carboxylates, sulfonates, sulfates or phosphates such as fatty acid soaps, lauryl sulfates and lauryl ether sulfates. Cationic surfactant Examples are aliphatic mono-, di- and polyamines, amine oxides, ethoxylated alkylamines and imidazolines derived from fatty acids and rosin acids. Examples of nonionic surfactants are polyoxyethylene surfactants, alkylphenol ethoxylates, carboxylates such as mono- and diglycerides, polyoxyethylene esters and fatty acid diethanolamine condensates. Amphoteric surfactants are those which contain a combination of the above anionic and cationic groups, especially those which contain both an acidic carboxyl group and a basic nitrogen group. Typical amphoteric surfactants are imidazolines and betaines such as lauric acid and myristic imidazoline and betaine, and amidinopropyl betaine.

The topical pharmaceutical composition may also contain a suitable emulsifier, meaning that it may enhance or promote the mixing and suspension of oil-in-water or water-in-oil. The emulsifier used herein may be a single emulsifier, or may be composed of a nonionic, anionic, cationic or amphoteric surfactant, or a blend of two or more such surfactants; preferably used herein as a nonionic With ionic emulsifiers. Such surfactants are described in "McCutcheon's Detergent and Emulsifiers," North American Edition, 1980 Annual published by the McCutcheon Division, MC Publishing Company, 175 Rock Road, Glen Rock, N.J. 07452, USA.

In the CTFA Cosmetic Ingredient Handbook, Second Edition (1992), a variety of non-limiting cosmetic ingredients commonly found in the skin care industry are described which are suitable for use in the compositions of the present invention. Examples of these ingredient classes include: abrasives, absorbents, aesthetic ingredients such as perfumes, pigments, colorants/colorants, essential oils, skin sensitizers, astringents, etc. (eg, clove oil, menthol, camphor, cilantro Oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agent, anti-caking agent, antifoaming agent, antibacterial agent For example, iodide propyl butyl carbamate), antioxidants, binders, biological additives, buffers, fillers, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturing agents a drug astringent, a topical analgesic, a film former or a material, such as a polymer, contributes to the film forming properties and durability of the composition (for example, a copolymer of eicosene and vinylpyrrolidone), Sunscreens, pH adjusters, propellants, reducing agents, chelating agents, skin conditioning agents (eg, wetting agents, including promiscuous and blocked), skin soothing agents and/or healing agents (eg, panthenol and derivatives) (eg, ethyl panthenol), aloe vera, pantothenic acid and derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin therapeutics, thickeners, and vitamins, and derivatives thereof.

Other skin conditions that may be treated or prevented by embodiments of the formulation are, for example, without limitation, dandruff and oily skin conditions.

The term "about" means ±10%. The term % w/w refers to the percentage of the weight of a particular ingredient in the weight of the overall formulation.

The term "dermatologically acceptable carrier", as used herein, means a carrier which is compatible with the skin, scalp, hair, nails and the like.

The term "prevention" means ensuring that the individual does not develop a disease, disorder or symptom. In some cases, an individual may have a risk of developing a disease but has not been diagnosed with the disease. In some cases, the term "prevention" means preventing the occurrence of a disease of the next cycle.

The plant extract used herein may be purified by a polar solvent such as ethyl alcohol (ethanol), butyl alcohol (butanol), methanol, water, or propanol, propylene glycol, butylene glycol, glycerol (ie, polar extraction). ()). The polar extract of the present invention may comprise any percentage of polar solvent.

Alternatively, the plant extract can be purified by a non-polar solvent such as, but not limited to, isooctane (i.e., a non-polar extract). The non-polar extract of the present invention may comprise any percentage of non-polar solvent.

Typically, hydrophobic molecules tend to be non-polar, so non-polar solvents are used. Hydrophilic molecules tend to be polar and can be dissolved by water and/or other polar substances.

The active ingredient can be concentrated from the extract using affinity chromatography, mass chromatography, and the like.

Typically, the plant extract of the invention is an aqueous extract. In order to obtain purified plant extracts (for example, organic salts of plant extracts, and/or heavy metals, and/or reduced starch content), aqueous plant extracts are generally further subjected to resin chromatography, such as macroporous Purified by resin or other chromatography methods. Glycerin, propylene glycol, butylene glycol or propylene glycol is added to the aqueous extract to assess the solubility of the extract, assess its skin penetration ability, and further preserve the extract. The extract may also contain a preservative.

Thus, according to another embodiment, there is provided a method of preparing a composition comprising a concentrated herbal extract for treating and/or preventing acne comprising: (a) placing the plant in 1-10 volumes of water To produce a plant extract; and (b) reducing the impurity content of the plant extract with a macroporous resin to increase the active ingredient content of the plant extract.

According to some embodiments, the formulation comprises any additional ingredients including solvents, emollients, humectants, blenders, viscosifiers, skin sedatives, emulsifiers, pH adjusters, preservatives, antioxidants, tackifiers, Perfumes, humectants, anti-acne agents, stabilizers and surfactants.

example Example 1 Formula for treating/preventing acne (concealer)

Example 2 Formula for treating/preventing acne (cream)

The pH of the above cream ranges from about 3.5 to 4.5.

Example 3 Formula for treating/preventing acne (cream)

Example 4 Formulation for treating/preventing acne (clean gel)

Example 5 Formula for treating/preventing acne (concealing treatment)

Example 6 Comparison of two cream formulas

Compare the two cream treatments. The ingredients of the first cream are detailed in Table II above, while the second cream with poor efficacy is detailed in Table VI below:

The pH of the cream of Table VI ranges from about 6.0 to 7.5.

The face cream was applied to six faces of six patients aged 28.7 ± 7.7 for six to seven days, with the first cream applied to half of the face and the second cream applied to the other half of the face.

Participants fill out the assessment questionnaire at the end of the trial period, which covers the following criteria: 1. the impact of the product on the number of papules; 2. the impact of the product on the severity of papules; 3. the impact of the product on oily skin; The effect of the product on skin redness; 5. The effect of the product on blackheads; 6. Overall appearance; 7. Overall evaluation of the product; and 8. Product texture.

Guidelines 1-5 can be evaluated as having: no impact, minimal impact, or significant impact; and criteria 6-8 can be evaluated as: poor, acceptable, good, and excellent.

The results of the treatment studies are shown in Figures 1A, 1B, 1C and 1D.

A comparison between Figures 1A and 1C, and between Figures 1B and 1D, shows treatment with a first cream compared to treatment with a second cream (described in detail in Table VI and illustrated in Figures 1C and 1D) Details are shown in Table II and are shown in Figures 1A and 1B), which are more effective and satisfactory in all standards, except for the effects of the product on blackheads, which are similar for both products.

Example 7 Comparison of two concealer treatment formulas

A comparison of the two concealer treatment recipes. The ingredients of the first concealer treatment formulation are detailed in Table I above, while the second cream is detailed in Table VII below:

The pH of the formulations listed in Table VII is between about 6 and 7.

The concealing treatment formula was applied twice a day to five faces of five patients aged 44.8 ± 10.3 for seven days, with the first cream applied to half of the face and the second cream applied to the other half of the face. The concealer treatment formula is considered a thick cream or ointment.

Participants fill out the assessment questionnaire at the end of the trial period, which covers the following criteria: 1. The effect of the product on the number of papules; 2. The effect of the product on the severity of papules; 3. The effect of the product on the redness of the skin; Overall appearance; 5. overall evaluation of the product; and 6. product texture.

Standards 1-3 can be evaluated as having no effect, minimal impact, or significant impact; and criteria 4-6 can be evaluated as: poor, acceptable, good, and excellent.

The results of the treatment studies are shown in Figures 2A, 2B, 2C and 2D. A comparison between Figures 2A and 2C, and between Figures 2B and 2D, shows treatment with a first cream compared to treatment with a second cream (described in detail in Table VII and illustrated in Figures 2C and 2D) Details are shown in Table I and shown in Figures 2A and 2B), which are more effective and satisfactory in all criteria, except for the effect of the product on skin redness, as the two products are similar.

Example 8 Comparison of herbal mixture with 0.5% salicylic acid and 0.5% salicylic acid

The half face of 28 individuals with acne was treated with a herbal mixture + 0.5% salicylic acid for 12 days, while the other half was treated with only 0.5% salicylic acid. The herbal mixture contains 1.5% Portulaca oleracea extract, 1.5% Palmetto rhubarb extract, 1.5% oil lily extract and 0.5% Astragalus root extract (xanthine).

The results are shown in Figure 3, which shows the percentage reduction in inflammatory acne lesions when treated with salicylic acid alone and with a combination of the above-described salicylic acid and herbal mixture. As shown in Figure 3, salicylic acid alone reduced only about 17% of the lesions, while treatment with the herbal mixture and salicylic acid reduced the inflammatory lesion by 32%.

Claims (20)

A topical formulation comprising Portulaca oleracea extract, Rheum palmatum extract, Chrysanthemum indicum extract and Scutellaria baicalensis root extract, or active ingredient thereof Baicalin, combined with nordihydroguaiaretic acid and oleanolic acid. The topical formulation of claim 1 is for the treatment or prevention of acne. The topical formulation of claim 1 further comprising one or more of the following: dipotassium glycyrrhizate, chamomile ( Chamomilla recutita (matricaria)) flower extract, and witch hazel (金缕梅) ( Hamamelis virginiana (witch hazel). The topical formulation of claim 1, which further comprises one or more of the following: salicylic acid, allantoin, and a-bisabolol. The topical formulation of claim 1 further comprising one or more of the following: kaolin, zinc oxide, hippophae rhamnoides oil, usnic acid, hydroxyphenyl propylamine Hydroxyphenyl propamidobenzoic acid, titanium dioxide. The topical formulation of claim 1 further comprising one or more of the following: imidazolidinyl urea, methylchloroisothiazolinone, and methylisothiazolinone. The topical formulation of any one of claims 3 and 4, wherein the formulation has The pH range is from about 3.5 to about 4.5. The topical formulation of claim 5 has a pH in the range of from about 7.0 to about 8.0. A topical formulation comprising a purslane extract, a sapindus mukorossi fruit extract, and at least one of the following: ammonium laureth sulfate, cocoamidopropyl betaine (cocamidopropyl betaine), cocamide MEA (cocamide MEA), cocamide DEA (cocamide DEA). A topical formulation according to claim 9 for use in the treatment or prevention of acne. The topical formulation of any one of claims 1 to 4, wherein the salicylic acid is present in an amount ranging from 0.5 to 2.0% w/w. A topical formulation as claimed in claim 1, wherein the formulation is a cream or concealer. A topical formulation as claimed in claim 9, wherein the formulation is a clean gel. The topical formulation of claim 12, wherein the topical formulation is a face cream, the combined concentration of the herbal extracts being at least 0.9% w/w. The topical formulation of claim 12, wherein the topical formulation is a concealer, the combined concentration of the herbal extracts is at least 9.0% w/w. A topical formulation according to claim 12, which contains at least 0.075% baicalin when the topical formulation is a face cream and at least 0.9% baicalin when the formula is a concealer. The topical formulation of claim 12, wherein the amount of each herbal extract is about 3% when the formulation is a concealing treatment formulation. The topical formulation of claim 12, wherein the amount of each herbal extract is about 0.3% when the formulation is a cream formulation. A topical formulation according to claim 1, wherein the formulation provides for reduction in sebum secretion, absorption of skin oil, anti-inflammatory activity, antibacterial activity, wound healing characteristics, antioxidant activity, reduction of skin irritation, skin absorption of the formula, or any thereof The synergistic utility of the combination. A method of treating acne comprising the step of topically applying a topical formulation of claim 1 to an individual in need thereof.